We are live on ! Find out more
GCVRZ

Sanofi Contingent Value Rights

Delisted

GCVRZ was delisted on the 3rd of March, 2020.

109 hedge funds and large institutions have $34.4M invested in Sanofi Contingent Value Rights in 2016 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 9 increasing their positions, 21 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

152% more capital invested

Capital invested by funds: $13.7M → $34.4M (+$20.8M)

44% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 9

3% more funds holding

Funds holding: 106109 (+3)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

57% less repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 21

Holders
109
Holders Change
+3
Holders Change %
+2.83%
% of All Funds
2.9%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
13
Increased
9
Reduced
21
Closed
9
Calls
Puts
Net Calls
Net Calls Change

GCVRZ Hedge Fund Activity: Q2 2016 in Review

109 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in Sanofi Contingent Value Rights (GCVRZ) for Q2 2016, worth a combined $34.4M — up 152% from $13.7M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new GCVRZ positions and 9 closed out — a net gain of 4 holders — while 9 added to existing stakes and 21 trimmed.

The largest buyer was TPG Group Holdings (SBS) Advisors, opening a new position worth an estimated $3.48M. The largest seller was UBS O'Connor, cutting an estimated $194K.

  • 109 institutional investors held Sanofi Contingent Value Rights (GCVRZ) as of Q2 2016, up from 106 in Q1 2016.
  • Funds reported $34.4M of Sanofi Contingent Value Rights stock for Q2 2016, up 152% quarter-over-quarter.
  • 13 funds opened new Sanofi Contingent Value Rights positions in Q2 2016 and 9 closed out, a net change of +4 holders.
  • The largest Sanofi Contingent Value Rights buyer in Q2 2016 was TPG Group Holdings (SBS) Advisors, an estimated $3.48M added.
  • The largest Sanofi Contingent Value Rights seller in Q2 2016 was UBS O'Connor, an estimated $194K sold.

Based on aggregated 13F filings for Q2 2016.